Thalassaemia Severity

计划入组 85 人 · 首次发布于 2024 年 12 月 6 日

Efficacy and safety of triple iron chelator (deferoxamine, deferasirox, and deferiprone) versus dual iron chelator (deferoxamine and deferasirox) combination therapy for reducing iron overload in transfusion-dependent beta-thalassaemia with very high iron overload.

Effectiveness of hydroxyurea treatment compared to placebo in reducing transfusions in beta-thalassaemia patients.

Beta thalassaemia therapeutic (ASC Therapeutics)

thalassemia therapeutics

β-thalassemia(Orna)

Chinese Base Editing Therapy Achieves First Clinical Cure of Beta Thalassaemia

NHS England Approves First CRISPR Gene-Editing Therapy for Beta Thalassaemia Treatment

NHS Patient Achieves Transfusion Independence Following CRISPR Gene Therapy for Beta Thalassaemia